Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$1.69M-73.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean A. McCarthy
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Beta
- 2.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.59
Financials
Revenue
$1.69M-73.1%Net Income
$-20.00MEBITDA
$-23.09MFree Cash Flow
$16.06M+1103.8%EPS (diluted)
$-0.09Shares Outstanding (diluted)
219.11M+499.7%Operating Expenses
$25.19MCash & Debt
$347.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $76.20M | $-17.37M | $-0.15 |
| 2024 | $138.10M | $31.87M | $0.38 |
| 2023 | $101.21M | $-569.0K | $-0.01 |
| 2022 | $53.16M | $-99.32M | $-1.48 |
| 2021 | $37.31M | $-115.87M | $-1.26 |
| 2020 | $68.43M | $-64.82M | $-0.71 |
| 2019 | $57.49M | $-102.24M | $-2.26 |
| 2018 | $59.50M | $-84.60M | $-2.03 |
| 2017 | $71.62M | $-43.10M | $-1.16 |
| 2016 | $15.04M | $-58.90M | $-1.63 |
| 2015 | $7.71M | $-35.37M | $-1.00 |
| 2014 | $5.08M | $-30.31M | $-0.87 |
| 2013 | $888.0K | $-15.14M | $-15.32 |
Valuation
CTMXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-60.00%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·9d ago·Negative
…ation that the issue has been addressed is needed. The competitive landscape in CRC for antibody-drug conjugates is heating up, although with recent updates passing, CTMX now has its opportunity to present its data.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call Transcript CytomX Therapeutics, Inc. ( CTMX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Chris Ogden - SVP, CFO & Secretary Sean McCarthy - Chairman & CEO Conference Call Participants Paul Jeng - Guggenheim Securities, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Olivia Brayer - …
View source ↗ - Newsmarketbeat.com·17d ago·Negative
CytomX Therapeutics Q3 Earnings Call Highlights CytomX Therapeutics NASDAQ: CTMX plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027.
View source ↗ - Newszacks.com·17d ago·Negative
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.
View source ↗ - Newsseekingalpha.com·17d ago·Neutral
CytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials CytomX Therapeutics is rated Buy, driven by positive clinical data for Varseta-M and a robust $367M cash runway after significant dilution. Varseta-M, targeting late-line colorectal cancer, achieved 20–32% ORR and 7 months PFS, securing FDA Fast Track and pivotal trial initiation in 1H 2027. Strategic partnerships with Amgen, Regeneron, and Moderna validate the PROBODY platform, with $6.7B in potential miles
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
CytomX Therapeutics to Present at Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
View source ↗ - Newsseekingalpha.com·102d ago·Negative
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX's pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.08 per share
Typical surprise -21.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.09 vs $-0.07miss
- Thu, Aug 6$-0.09 vs $-0.08miss
- Thu, May 7$-0.10 vs $-0.14beat
- Mon, Mar 16$-0.22 vs $-0.08miss
- Thu, Nov 6$-0.09 vs $-0.05miss
- Thu, Aug 7$-0.00 vs $-0.06beat
Estimates and results for CTMX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CTMX officers and directors.
- Bought
- —
- Sold
- $2.5m
0 trades
21 trades
- Ogden Christophersold
- Chu Yu-wayesold
- Mccarthy Sean A.sold
- Belvin Marciasold
- Ogden Christophersold
- Mccarthy Sean A.sold
- Mccarthy Sean A.sold
- Ogden Christophersold
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CTMX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
